Blueprint Medicines (BPMC) Misses Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
Blueprint Medicines (BPMC) PT Raised to $70 at Wedbush
November 1, 2017 7:17 AM EDTWedbush analyst David Nierengarten raised his price target on Blueprint Medicines (NASDAQ: BPMC) to $70.00 (from $66.00) while maintaining a Outperform rating after the company reported enrollment progress across a number of studies of their wholly-owned kinase assets, and reiterated timeline for future trial... More
